These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30848278)

  • 1. Poloxin-2HT+: changing the hydrophobic tag of Poloxin-2HT increases Plk1 degradation and apoptosis induction in tumor cells.
    Rubner S; Schubert S; Berg T
    Org Biomol Chem; 2019 Mar; 17(12):3113-3117. PubMed ID: 30848278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Degradation of Polo-like Kinase 1 by a Hydrophobically Tagged Inhibitor of the Polo-Box Domain.
    Rubner S; Scharow A; Schubert S; Berg T
    Angew Chem Int Ed Engl; 2018 Dec; 57(52):17043-17047. PubMed ID: 30351497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized Plk1 PBD Inhibitors Based on Poloxin Induce Mitotic Arrest and Apoptosis in Tumor Cells.
    Scharow A; Raab M; Saxena K; Sreeramulu S; Kudlinzki D; Gande S; Dötsch C; Kurunci-Csacsko E; Klaeger S; Kuster B; Schwalbe H; Strebhardt K; Berg T
    ACS Chem Biol; 2015 Nov; 10(11):2570-9. PubMed ID: 26279064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB; Woo SU; Yim H
    J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
    Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
    Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.
    Yuan J; Sanhaji M; Krämer A; Reindl W; Hofmann M; Kreis NN; Zimmer B; Berg T; Strebhardt K
    Am J Pathol; 2011 Oct; 179(4):2091-9. PubMed ID: 21839059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
    Kreis NN; Louwen F; Zimmer B; Yuan J
    Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
    Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
    Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.
    Chapagai D; Ramamoorthy G; Varghese J; Nurmemmedov E; McInnes C; Wyatt MD
    J Med Chem; 2021 Jul; 64(14):9916-9925. PubMed ID: 34210138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
    Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
    Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells.
    Ritter A; Friemel A; Kreis NN; Louwen F; Yuan J
    Oncotarget; 2016 Dec; 7(51):84271-84285. PubMed ID: 27713178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
    Craig SN; Baxter M; Chapagai D; Stafford JM; Nurmemmedov E; Altomare D; Wyatt MD; McInnes C
    Eur J Med Chem; 2022 Jan; 227():113926. PubMed ID: 34735919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of nitroimidazole-oxime derivatives targeting the polo-box domain of polo-like kinase 1.
    Sun J; Liu HY; Xu RF; Zhu HL
    Bioorg Med Chem; 2017 Dec; 25(24):6581-6588. PubMed ID: 29100732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay.
    Normandin K; Lavallée JF; Futter M; Beautrait A; Duchaine J; Guiral S; Marinier A; Archambault V
    Sci Rep; 2016 Nov; 5():37581. PubMed ID: 27874094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators.
    Archambault V; Normandin K
    Cell Cycle; 2017 Jun; 16(12):1220-1224. PubMed ID: 28521657
    [TBL] [Abstract][Full Text] [Related]  

  • 16.  p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
    Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
    Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
    Lv X; Yang X; Zhan MM; Cao P; Zheng S; Peng R; Han J; Xie Z; Tu Z; Liao C
    Eur J Med Chem; 2019 Dec; 184():111769. PubMed ID: 31629162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
    Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
    PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
    Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
    Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
    Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG
    Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.